Navigation Links
Auxilium Pharmaceuticals to Announce Third Quarter 2013 Results on November 6, 2013
Date:10/24/2013

CHESTERBROOK, Pa., Oct. 24, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, will release results for the third quarter 2013 on Wednesday, November 6, 2013. The Company will also conduct a conference call that day at 10:00 a.m. ET to discuss results and highlights of the third quarter.  The presentation slides to be used during the call will be available on the "For Investors" section of the Company's web site under the "Presentations" tab beginning at 7:00 a.m. ET on Wednesday, November 6, 2013.  A web cast of the conference call and the presentation slides will be available on the "For Investors" section of the Company's web site under the "Events" tab beginning at 10:00 a.m. ET on Wednesday, November 6, 2013.  A question and answer session will follow the presentation. 

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

Mr. Adrian Adams, Chief Executive Officer and President, will host the conference call.Conference call details:Date:

Wednesday, November 6, 2013Time:10:00 a.m. ETDial-in (U.S.):

800-510-0219Dial-in (International):

617-614-3451Web cast:

http://www.auxilium.comPasscode:

AUXILIUMTo access an audio replay of the call:Access number (U.S.):

888-286-8010 Access number (International):

617-801-6888Replay Passcode #:

90298181About AuxiliumAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences.  Auxilium markets Testim® (testosterone gel) for the topical treatment of hypogonadism in the U.S. and XIAFLEX (collagenase clostridium histolyticum or CCH) for the treatment of adult Dupuytren's contracture patients with a palpable cord in the U.S. Ferring International Center S.A. markets Testim in certain countries of the EU and Paladin Labs Inc. markets Testim in Canada.  Swedish Orphan Biovitrium AB has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 71 Eurasian and African countries.  Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico.  Auxilium also markets TESTOPEL®, a long-acting implantable testosterone replacement therapy, Edex®, the leading branded non-oral drug for erectile dysfunction, Striant®, a buccal system for testosterone delivery, Osbon ErecAid®, the leading device for aiding erectile dysfunction, and also has a non-promoted respiratory franchise, including Theo-24® and Semprex®-D, along with three other non-promoted products, in the U.S.  Auxilium has exclusive marketing rights in the U.S. and Canada for STENDRATM, an oral erectile dysfunction therapy.  Auxilium has three projects in clinical development.  XIAFLEX is currently under regulatory review by the U.S. FDA for the treatment of Peyronie's disease.  CCH is in Phase 2 of development for the treatment of Frozen Shoulder syndrome (adhesive capsulitis) and Phase 2 of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy).  Auxilium also has rights to pursue additional indications for XIAFLEX. For additional information, visit http://www.auxilium.com.

AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including statements made with respect to Auxilium's strategy, progress and timing of development programs and related trials, the efficacy of its product candidates, the commercial benefits available to it as a result of its agreements with third parties, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words.  Although forward-looking statements are based on Auxilium's current plans or assessments that are believed to be reasonable as of the date of this press release, they inherently involve certain risks and uncertainties. These forward-looking statements are subject to a number of risks and uncertainties, including those discussed in Auxilium's filings with the Securities and Exchange Commission (the "SEC"). While Auxilium may elect to update the forward-looking statements made in this news release in the future, Auxilium specifically disclaims any obligation to do so.  Auxilium's SEC filings may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov.  There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements.

AUXILIUM CONTACTS: James E. Fickenscher / CFO
Nichol Ochsner/ Senior Director, IR 
Auxilium Pharmaceuticals, Inc.
Auxilium Pharmaceuticals, Inc. 
(484) 321-59
(484) 321-5900
jfickenscher@auxilium.com
nochsner@auxilium.com


'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Acquisitions, Clinical Trial Results, Date Extensions and Financial Results - Research Report on Endo, Astex, Auxilium, Accuray, and BioScrip
2. BioSpecifics Technologies Corp. Announces Partnership between Auxilium and Swedish Orphan Biovitrum AB for XIAPEX in Eurasia and Africa
3. Auxilium Pharmaceuticals, Inc. To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
4. Auxilium, Inc. Launches Top-Tier Engineer Program
5. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
6. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
7. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
8. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
9. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
10. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
11. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Biologist Dawn Maslar MS has ... her latest book, Men Chase, Women Choose: The Neuroscience of Meeting, Dating, Losing Your ... physiological effect on men. ”The logical next step, in my estimation, was to scientifically ...
(Date:6/20/2017)... , June 20, 2017  Kibow Biotech Inc., ... to announce the issuance of a new patent covering ... hyperuricemia by the U.S. Patent and Trademark Office on ... winner of the Buzz of Bio award in 2014 ... akin to developing non-drug approaches to chronic disease. Renadyl™, ...
(Date:6/20/2017)... ... June 20, 2017 , ... Do More with OHAUS , With the launch ... supplier in the weighing industry, to extending its expertise across the entire laboratory to ... hybridizations and more, allowing for its customers to 'Do More' in the ...
(Date:6/19/2017)... ... 2017 , ... As Vice President, Product Services, Mr. Guinter ... support, and client process and SOP development. , Mr. Guinter brings a wealth ... for service providers and top-tier pharmaceuticals, and as an independent consultant supported a ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
Breaking Biology News(10 mins):